The current biological age tests are inferior in some ways, possibly relying too much on association and fake U-shape curves (For those who don’t know, U-shape curves show lots of dubious assosciations like being overweight, and having high LDL, glucose, blood pressure, and so on all are good for “longevity” than normal or low, when there is reverse causation and confounding factors in many cases.)
I think the first step either way is someone figures out a really good longevity score based on blood tests that considers causal factors like apoB, non-HDL-c and heart disease, and weighs accurately the differents parts of the longevity or healthspan score based on level and quality of evidence.
Then people if some service allows API access upload this data before initiating treatment, or enter manually. This calculates longevity or healthspan score. Then a person initiates treatment and uploads again after some period. Change is marked. Person can share or group this together with other people if they wish, it can probably be done in some way for other rapamycin users and we have mean change in this score if there is any.
If people are really enthusiastic and there’s plenty of users (so there are some enthusiastic users) the treatment can be done in a blinded fashion with QR codes like the microdosing LSD experiment. NYT readers are going to fall off their chairs if/when they see a blinded improvement in longevity score for any treatment, it might be a future longevity drug or combo from the wormbot experiments.
But either way… there needs to be a good longevity score or healthspan score even maybe someone like Peter Attia would consider who is probably more evidence-based or traditional.
This longevity score + open source + platform could easily allow people to test future compounds with more potential than rapamycin or combinations (like those maybe found in the wormbot experiments: Super longevity drugs coming soon 2027-2028)
The bottleneck is otherwise going to be human testing, new outcome (longevity score), and so on.